TG Therapeutics(TGTX)
NEW YORK, NYBiotechnology
Focus: TG Therapeutics is a publicly traded biotech company focused on biologics for oncology, neurology, and immunology, with a diversified pipeline anchored by one commercial product.
Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
1+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at TG Therapeutics?
AI assessmentTG Therapeutics is a clinical-stage biotech in transition to commercial maturity, offering exposure to multiple late-stage programs and early-stage profitability, but with execution risk tied to pipeline advancement and modest near-term hiring velocity.
Why Work Here
- Dramatic revenue inflection: FY2025 revenue reached $234M vs. $3M in FY2024, signaling commercial momentum from UKONIQ launch
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$234M
Key Products
Growing
Peak8.9yr
Sole marketed product driving FY2025 $234M revenue; exclusivity extends to 2035, providing long-term cash generation runway.
Help build intelligence for TG Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.